Difficile Infection

The FDA has approved Vowst, the first orally administered fecal microbiota product indicated for the prevention of recurrent Clostridioides difficile infection in adults following antibacterial treatment.

SER-109, an investigational oral microbiome therapeutic, was well-tolerated and durably reduced rates of recurrent Clostridioides difficile infection through 24 weeks, with benefits showing as early as week 2, data show.

Although the prevalence of Clostridioides difficile infection in the U.S. continued its long-term downward trend during the COVID-19 pandemic, patients who were infected saw high treatment costs and increased mortality, a study found.

An investigational oral microbiome therapeutic was superior to placebo in reducing the risk for recurrent Clostridioides difficile infection among patients with three or more episodes, according to the results of a phase 3 trial.

In this Healio Gastroenterology video exclusive, Jessica R. Allegretti, MD, MPH, director of the fecal microbiota center at Brigham and Women’s Hospital, discussed treatment options for recurrence for Clostridioides difficile infection.

LAS VEGAS — CP101, an investigational microbiome therapeutic, restored microbiome diversity and prompted a sustained clinical cure among patients with recurrent Clostridioides difficile infection, according to a presentation.

Using a new highly sensitive assay, researchers demonstrated that the amount of toxin in stool correlates with the severity of Clostridioides difficile infection, with higher concentrations associated with severe disease at diagnosis.

Reduced susceptibility to metronidazole was associated with decreased clinical response rates in patients with Clostridioides difficile infection, according to a study published in Open Forum Infectious Diseases.

ACG developed guidelines for the preferred management of adults with Clostridioides difficile infection, published in the American Journal of Gastroenterology.